Neuroprogression and Staging in Bipolar Disorder provides a comprehensive summary of the current state of the evidence regarding the use of staging systems in bipolar disorder. Edited by the leading researchers in the field, the book systematically covers the theoretical basis for staging, comparisons between different proposals, neurobiological underpinnings, the current evidence-base, limitations and future directions, and clinical implications and recommendations for practice. The book provides a solid and in-depth outline and thus to influence research and practice in the field of bipolar disorder.
Flavio Kapczinski, Clinical Hospital of Porto Alegre, Brazil,Eduard Vieta,University of Barcelona, Spain,Pedro V. S. Magalhaes, Clinical Hospital of Porto Alegre, Brazil,Michael Berk,Deakin University, Melbourne, Australia
Flavio Kapczinski is Professor of Psychiatry, Director of Research and Head of the Molecular Psychiatry Laboratory at the Hospital de Clinicas de Porto Alegre, Brazil. He is Consultant for the National Council of Scientific and Technological Development (CNPq). He has wide experience in clinical research, being lead investigator in several clinical trials, some funded by the Stanley Medical Research Institute and Brain & Behavioral Foundation. His work identified biological underpinnings of the decline in cognition and physical health among patients with bipolar disorder. He has published over 302 peer-reviewed papers and has 4700 citations with an H-index of 35. Recently his research has focused on neurotoxicity mechanisms linked to mood episodes and the use of a systemic toxicity index, supporting the notion that bipolar disorder is a systemic illness, approximating psychiatry to other fields of medicine. He currently coordinates the Brazilian National Institute of Translational Medicine.
Eduard Vieta is Professor of Psychiatry, Head of Department and Director of the Bipolar Disorders Program of the Hospital Clinic at the University of Barcelona, Spain. He is Director of the Bipolar Research Program at the Spanish Research Network on Mental Diseases (CIBERSAM) funded by the Spanish Ministry of Science and Innovation. His research focuses on the neurobiology, epidemiology and treatment of bipolar disorder. He received the 2007 Aristotle Award, the 2005 Mogens Schou Award and the 2012 Colvin Prize on Outstanding Achievement in Mood Disorders Research by the Brain and Behaviour Research Foundation. Having made significant contributions to many published bipolar disorder treatment guidelines he has authored over 500 articles, 200 chapters and 27 books. His H index is 58 with over 12000 citations. He is on editorial boards of many international scientific journals. He has served as Invited Professor at Harvard University and Neuroscience Scientific Advisor to the European Presidency.
Pedro V. S. Magalhaes currently serves as Post-Doctoral Research Fellow in translational psychiatry at the National Institute for Translational Medicine in Brazil, before which he was Assistant Professor of Physiology, Biostatistics and Pharmacology at LaSalle University, Canoas from 2011 to 2012. In 2012 he received the Ministry of Education and Culture of Brazil Award for best doctoral thesis of 2011 (Medicine II) and the Samuel Gershon Award for Young Investigator (International Society for Bipolar Disorders). The fundamental nexus of his research career has been an effort for using research methods effectively in the investigation of bipolar disorder. He also holds the post of Junior Editor at RBP Psychiatry. The main lines of research he has developed and continues in recent years include translational medicine and epidemiology, clinical trials and systematic reviews.
Michael Berk is Professor and Alfred Deakin Chair of Psychiatry at Deakin University and Honorary Professorial Research Fellow in the Department of Psychiatry at the Florey Institute for Neuroscience and Mental Health and Orygen Youth Health at Melbourne University. He has published over 450 papers on mood disorders, his greatest contribution being the discovery and implementation of novel therapies. He has published 25 self-initiated randomised controlled trials, pioneering randomised placebo controlled trials of N-acetyl cysteine in depression and bipolar disorder maintenance treatment, establishing an entirely new treatment and implicating a novel mechanism of disease. He was founding editor of the Journal of Depression and Anxiety and has been involved with 12 other journals. He holds gra